Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 2/20 | 0.49 |
| ▸ | CES1 | P23141 | 2/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3959724 | 0.80 | DAO (0.52) | CYP2C9CYP2C19TSHRCYP2D6CES2 | |
| SCHEMBL81393 | 0.80 | CYP2C9 (0.55) | CYP2C9CYP2C19TSHRCYP2D6CES2 | |
| SCHEMBL3197028 | 0.76 | TSHR (0.58) | CYP2C9CYP2C19TSHRCYP2D6CES2 | |
| SCHEMBL8298426 | 0.73 | TSHR (0.55) | CYP2C9CYP2C19TSHRCYP2D6CES2 | |
| SCHEMBL3839189 | 0.73 | DAO (0.55) | CYP2C9CYP2C19TSHRCYP2D6CES2 | |
| Hydrochloric Acid SCHEMBL4126481 | 0.72 | TSHR (0.54) | CYP2C9CYP2C19TSHRCYP2D6CES2 | |
| SCHEMBL14490190 | 0.72 | CES2 (0.61) | CYP2C9CYP2C19TSHRCYP2D6CES2 | |
| SCHEMBL29077328 | 0.72 | CES2 (0.61) | CYP2C9CYP2C19TSHRCYP2D6CES2 | |
| SCHEMBL5179085 | 0.72 | TSHR (0.53) | CYP2C9CYP2C19TSHRCYP2D6CES2 | |
| SCHEMBL26056789 | 0.72 | CES2 (0.66) | CYP2C9CYP2C19TSHRCYP2D6CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7527809-B2 | Polyhydroxyalkanoate-containing magnetic structure, and manufacturing method and use thereof | CANON KABUSHIKI KAISHA (JP) | 2009-05-05 | — | — | US | disclosed |
| US-20060263432-A1 | Useful as a sustained release pharmaceutical preparation; microcapsule stably containing a drug, especially a water-soluble drug at high content and which has magnetic property; drug delivery; excellent in dispersibility and magnetic response | CANON KABUSHIKI KAISHA (JP) | 2006-11-23 | — | — | US | disclosed |
| WO-2004096188-A1 | POLYHYDROXYALKANOATE-CONTAINING MAGNETIC STRUCTURE, AND MANUFACTURING METHOD AND USE THEREOF | CANON KABUSHIKI KAISHA (JP) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060263432-A1 | Useful as a sustained release pharmaceutical preparation; microcapsule stably containing a drug, especially a water-soluble drug at high content and which has magnetic property; drug delivery; excellent in dispersibility and magnetic response | SKP1, HAMP, AUP1 | CYP2C9 1804/4885CYP2C19 608/4885TSHR 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.